<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03457818</url>
  </required_header>
  <id_info>
    <org_study_id>AAAR7827</org_study_id>
    <nct_id>NCT03457818</nct_id>
  </id_info>
  <brief_title>Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab</brief_title>
  <official_title>Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mishaela Rubin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to characterize the effect of Prolia® (denosumab) on indices of bone&#xD;
      strength in type 2 diabetes (T2D). The investigational plan involves administration of&#xD;
      Prolia® or identical placebo for 12 months as a randomized double-blind placebo-controlled&#xD;
      trial in 66 T2D postmenopausal women assigned to Prolia® or placebo. The study will include&#xD;
      assessment of different measures of bone quality: skeletal microarchitecture, including&#xD;
      measurement of skeletal cortical pores; bone mineral density; bone material quality, and&#xD;
      accumulation of advanced glycation endproducts (AGEs) in collagen. This information will help&#xD;
      to determine whether Prolia® treatment in type 2 diabetes has skeletal benefits.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 Diabetes Mellitus (T2DM) has become one of the most important diseases of our time.&#xD;
      Recent research shows that diabetes has negative effects on bones and that people with&#xD;
      diabetes might be more likely to break a bone. We don't know the reasons for this, but we&#xD;
      suspect that normal bone replacement is slowed down in diabetes and this could slow down the&#xD;
      growth of new bone. It is possible that the normal bone material becomes weaker because&#xD;
      sugar-related components (&quot;Advanced Glycation Endproducts&quot;) are making the bone more brittle.&#xD;
      The investigators have shown in past research that people who have type 2 diabetes are more&#xD;
      likely to have both weaker bone with lower &quot;bone material strength&quot; and also higher levels of&#xD;
      sugar-related components (&quot;Advanced Glycation Endproducts&quot;). This study will focus on&#xD;
      attempting to lower the sugar-related components (&quot;Advanced Glycation Endproducts&quot;) by&#xD;
      treating a group of patients with type 2 diabetes with a medication Prolia® or denosumab for&#xD;
      one year. The investigators will compare postmenopausal women both before and after denosumab&#xD;
      use and study them in terms of different bone features based on blood tests, bone imaging, a&#xD;
      bone indentation test and a measurement of sugar-related components in the skin. This study&#xD;
      will help to clarify if using this medication helps improve bone strength in women with&#xD;
      diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to enrollment difficulties compounded by the COVID pandemic.&#xD;
  </why_stopped>
  <start_date type="Actual">November 7, 2018</start_date>
  <completion_date type="Actual">June 10, 2020</completion_date>
  <primary_completion_date type="Actual">June 10, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study is a 12 month randomized (2:1 assignment) double-blind placebo-controlled trial of T2D postmenopausal women assigned to either Denosumab 60 mg subcutaneously (SC) at baseline and 6 months (n=44) or placebo (n=22); total study n=66.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Clinical Research Coordinators</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cortical Porosity (Ct.Po) (%) by High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Imaging From Baseline to 6 and 12 Months.</measure>
    <time_frame>Baseline, 6 months and 12 months</time_frame>
    <description>The primary outcome is the 12 months change in Ct.Po and the primary intent-to-treat analysis is a one-way ANCOVA with the fixed effect of treatment (treated vs. placebo), and baseline Ct.Po as a continuous covariate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Collagen Type I C-Telopeptide (s-CTX) (ng/ml) and Tartrate-resistant Acid Phosphatase 5b (TRAP 5b) (ng/ml) by Blood Test From Baseline to 3, 6 and 12 Months.</measure>
    <time_frame>Baseline, 3 months, 6 months and 12 months</time_frame>
    <description>Secondary outcomes will be analyzed using ANCOVA models with P-value adjustment for multiple endpoint comparisons.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dual-energy X-ray Absorptiometry (DXA) (gm/cm2) at Lumbar Spine, Femoral Neck, Total Hip and Radius From Baseline to 6 and 12 Months.</measure>
    <time_frame>Screening visit, 6 months and 12 months</time_frame>
    <description>Secondary outcomes will be analyzed using ANCOVA models with P-value adjustment for multiple endpoint comparisons.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Skin Autofluorescence (SAF) (Unitless) From Baseline to 6 and 12 Months.</measure>
    <time_frame>Baseline, 6 months and 12 months</time_frame>
    <description>Exploratory outcomes will be analyzed using ANCOVA models with P-value adjustment for multiple endpoint comparisons.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Denosumab 60 mg/ml [Prolia] SC at baseline and 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo SC at Baseline and 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab 60 mg/ml [Prolia]</intervention_name>
    <description>Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Prolia®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. An understanding, ability and willingness to fully comply with study procedures and&#xD;
             restrictions.&#xD;
&#xD;
          2. Ability to voluntarily provide written, signed and dated informed consent as&#xD;
             applicable to participate in the study.&#xD;
&#xD;
          3. Postmenopausal women age ≥ 50 and ≤ 90 years at time of consent.&#xD;
&#xD;
          4. Diagnosis of T2D for ≥ 2 years. Upon review of patient's medical history, patient will&#xD;
             be confirmed to currently have reasonably controlled T2D as assessed by the&#xD;
             investigator, with HbA1c ≤ 8.4%. If HbA1c is ≥ 8.5%, re-screening will be allowed&#xD;
             after approximately 3 months following adjustment of diabetes therapy.&#xD;
&#xD;
          5. DXA T-score ≤ -1.0 at one or more sites (lumbar spine, femoral neck, total hip or&#xD;
             distal 1/3 radius).&#xD;
&#xD;
          6. Normal albumin-adjusted serum calcium level.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hormone replacement treatment use (to avoid the influence of estrogen).&#xD;
&#xD;
          2. Fractures (excluding skull, facial bones, metacarpals, fingers, toes, and fractures&#xD;
             associated with severe trauma) within 12 months.&#xD;
&#xD;
          3. A history of pathological fractures (eg, due to Paget's disease, myeloma, metastatic&#xD;
             malignancy).&#xD;
&#xD;
          4. Type 1 diabetes.&#xD;
&#xD;
          5. Disorders associated with altered skeletal structure or function (chronic renal&#xD;
             disease stage 4 or worse, chronic liver disease, malignancy, hypoparathyroidism or&#xD;
             hyperparathyroidism, acromegaly, Cushing's syndrome, hypopituitarism, chronic&#xD;
             obstructive pulmonary disease, alcohol intake &gt; 3 units/day).&#xD;
&#xD;
          6. Treatment with any of the following drugs in past year: anticonvulsant therapy,&#xD;
             pharmacological doses of thyroid hormone (TSH&lt;normal is permitted if subject has&#xD;
             normal T4, clinical euthyroidism and is in steady-state), adrenal or anabolic&#xD;
             steroids, calcitonin, estrogen or selective estrogen receptor modulator, sodium&#xD;
             fluoride (other than dental treatment), teriparatide, denosumab, abaloparatide,&#xD;
             strontium or aromatase inhibitors; any history of bisphosphonate treatment.&#xD;
             Corticosteroid use permitted if subject is in steady-state.&#xD;
&#xD;
          7. Serum 25(OH)D levels &lt; 20 ng/ml. If 25(OH)D levels are &lt; 20 ng/ml, rescreening will be&#xD;
             allowed following a vitamin D loading regimen of 50,000 IU/week for 4 weeks. If serum&#xD;
             25(OH)D levels are ≥ 20 ng/ml after supplementation, the subject will be allowed to&#xD;
             enroll.&#xD;
&#xD;
          8. Clinically significant hypersensitivity to denosumab or any components of denosumab 60&#xD;
             mg.&#xD;
&#xD;
          9. Known sensitivity to any of the products to be administered during the study (e.g.,&#xD;
             calcium or vitamin D).&#xD;
&#xD;
         10. Subject is pregnant or breast feeding, or planning to become pregnant within 5 months&#xD;
             after the end of treatment.&#xD;
&#xD;
         11. Female subject of child bearing potential and is not willing to use, in combination&#xD;
             with her partner, highly effective contraception during treatment and for 5 months&#xD;
             after the end of treatment.&#xD;
&#xD;
         12. Significant dental/oral disease, including prior history or current evidence of&#xD;
             osteonecrosis/osteomyelitis of the jaw, or the following:&#xD;
&#xD;
               -  Active dental or jaw condition which requires oral surgery&#xD;
&#xD;
               -  Non-healed dental/oral surgery&#xD;
&#xD;
               -  Planned invasive dental procedures for the course of the study&#xD;
&#xD;
         13. DXA T-score of ≤ -3.5 at any site.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mishaela Rubin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center - Harkness Pavillion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, Johnson KC, Margolis KL. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab. 2006 Sep;91(9):3404-10. Epub 2006 Jun 27.</citation>
    <PMID>16804043</PMID>
  </reference>
  <reference>
    <citation>Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int. 2007 Apr;18(4):427-44. Epub 2006 Oct 27. Review.</citation>
    <PMID>17068657</PMID>
  </reference>
  <reference>
    <citation>Furst JR, Bandeira LC, Fan WW, Agarwal S, Nishiyama KK, McMahon DJ, Dworakowski E, Jiang H, Silverberg SJ, Rubin MR. Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes. J Clin Endocrinol Metab. 2016 Jun;101(6):2502-10. doi: 10.1210/jc.2016-1437. Epub 2016 Apr 26.</citation>
    <PMID>27115060</PMID>
  </reference>
  <reference>
    <citation>Zebaze R, Libanati C, McClung MR, Zanchetta JR, Kendler DL, Høiseth A, Wang A, Ghasem-Zadeh A, Seeman E. Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis. J Bone Miner Res. 2016 Oct;31(10):1827-1834. doi: 10.1002/jbmr.2855. Epub 2016 May 19.</citation>
    <PMID>27082709</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>March 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2018</study_first_posted>
  <results_first_submitted>April 17, 2021</results_first_submitted>
  <results_first_submitted_qc>April 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 11, 2021</results_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Mishaela Rubin</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Prolia</keyword>
  <keyword>Denosumab</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 17, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03457818/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment Group</title>
          <description>Denosumab 60 mg/ml [Prolia] SC at baseline and 6 months.&#xD;
Denosumab 60 mg/ml [Prolia]: Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Placebo SC at Baseline and 6 months.&#xD;
Placebo: Placebo will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Study terminated</participants>
                <participants group_id="P2" count="0">study terminated</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study terminated</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment Group</title>
          <description>Denosumab 60 mg/ml [Prolia] SC at baseline and 6 months.&#xD;
Denosumab 60 mg/ml [Prolia]: Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Placebo SC at Baseline and 6 months.&#xD;
Placebo: Placebo will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="14"/>
                    <measurement group_id="B2" value="69.5" spread="7"/>
                    <measurement group_id="B3" value="69" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Cortical Porosity (Ct.Po) (%) by High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Imaging From Baseline to 6 and 12 Months.</title>
        <description>The primary outcome is the 12 months change in Ct.Po and the primary intent-to-treat analysis is a one-way ANCOVA with the fixed effect of treatment (treated vs. placebo), and baseline Ct.Po as a continuous covariate.</description>
        <time_frame>Baseline, 6 months and 12 months</time_frame>
        <population>Study terminated</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Denosumab 60 mg/ml [Prolia] SC at baseline and 6 months.&#xD;
Denosumab 60 mg/ml [Prolia]: Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Placebo SC at Baseline and 6 months.&#xD;
Placebo: Placebo will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cortical Porosity (Ct.Po) (%) by High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Imaging From Baseline to 6 and 12 Months.</title>
          <description>The primary outcome is the 12 months change in Ct.Po and the primary intent-to-treat analysis is a one-way ANCOVA with the fixed effect of treatment (treated vs. placebo), and baseline Ct.Po as a continuous covariate.</description>
          <population>Study terminated</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Collagen Type I C-Telopeptide (s-CTX) (ng/ml) and Tartrate-resistant Acid Phosphatase 5b (TRAP 5b) (ng/ml) by Blood Test From Baseline to 3, 6 and 12 Months.</title>
        <description>Secondary outcomes will be analyzed using ANCOVA models with P-value adjustment for multiple endpoint comparisons.</description>
        <time_frame>Baseline, 3 months, 6 months and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Dual-energy X-ray Absorptiometry (DXA) (gm/cm2) at Lumbar Spine, Femoral Neck, Total Hip and Radius From Baseline to 6 and 12 Months.</title>
        <description>Secondary outcomes will be analyzed using ANCOVA models with P-value adjustment for multiple endpoint comparisons.</description>
        <time_frame>Screening visit, 6 months and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Skin Autofluorescence (SAF) (Unitless) From Baseline to 6 and 12 Months.</title>
        <description>Exploratory outcomes will be analyzed using ANCOVA models with P-value adjustment for multiple endpoint comparisons.</description>
        <time_frame>Baseline, 6 months and 12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>Denosumab 60 mg/ml [Prolia] SC at baseline and 6 months.&#xD;
Denosumab 60 mg/ml [Prolia]: Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Placebo SC at Baseline and 6 months.&#xD;
Placebo: Placebo will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>vaginal yeast infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mishaela Rubin</name_or_title>
      <organization>Columbia University</organization>
      <phone>2019528237</phone>
      <email>mrr6@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

